US study confirms effectiveness of quadrivalent human papillomavirus (HPV) vaccine in women aged up to 20 years who receive all three doses, but more research is needed in women aged 21-26 years.
US study confirms effectiveness of quadrivalent human papillomavirus (HPV) vaccine in women aged up to 20 years who receive all three doses, but more research is needed in women aged 21-26 years.